Saxagliptin hydrate

Description: Saxagliptin hydrate (also known as BMS-477118 hydrate, Onglyza hydrate, BMS 477118 hydrate, BMS477118 hydrate; brand name: Onglyza), the hydrate form of Saxagliptin, is a potent, orally bioactive, selective and reversible DPP4 (dipeptidyl peptidase-4) inhibitor with IC50 of 26 nM. Saxagliptin was approved in 2008 by FDA for the treatment of type 2 diabetes. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus. In vitro, saxagliptin inhibits FBS-, insulin- and IGF1-induced ERK phosphorylation and cell proliferation, in both MSC and MC3T3E1 preosteoblasts. In the absence of growth factors, saxagliptin has no effect on ERK activation or cell proliferation.

References: Am J Health Syst Pharm. 2010 Sep 15; 67(18):1515-25; Vascul Pharmacol. 2016 Jan; 76:62-71.

Related CAS#: 361442-04-8 (free base); 709031-78-7 (HCl); 1073057-20-1 (HCl hydrate); 1073057-33-6 (benzoate hydrate)

Chemical Name: (1S, 3S, 5S)-2-((S)-2-amino-2-((1r, 3R, 5R, 7S)-3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrate

InChi Key: AFNTWHMDBNQQPX-IGSRIJEQSA-N

InChi Code: InChI=1S/C18H25N3O2.H2O/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23, 6-10)9-17; /h10-15, 23H, 1-7, 9, 20H2; 1H2/t10-, 11+, 12-, 13+, 14+, 15-, 17+, 18-; /m1./s1

SMILES Code: N#C[CH]1N(C([CH](N)[C]23C[C]4(O)C[C](C3)([H])C[C](C4)([H])C2)=O)[C]5([H])C[C]5([H])C1.[H]O[H]